Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

For 13 years, Marks led the FDA's Center for Biologics Evaluation and Research, the department in charge of reviewing and approving vaccines, genetic medicines and cell therapies.Please watch the ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Peter Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines, will leave ...

(Reuters) -Shares of U.S. drugmakers fell before the bell on Monday after reports that the Food and Drug Administration's top ...

The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy ...